Kailera Therapeutics, Inc.
NASDAQ:KLRABiotechnology
+$0.51 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.42M
Average 0.80M
KLRA Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Kailera Therapeutics, Inc.NASDAQ: KLRA
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity of $1.12B in Q2 FY2026
Q2 FY2026 total equity was $1.12B.
Context
- Total equity amounted to 92.3% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (356.46M) USD
- Year-over-year change
- —
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (356.46M) | — |
Total Equity vs competitors
How KLRA compares with its peers on the latest reported figures
- KLRA's Jun 2026 total equity of $1.12B is the highest of the 10 companies compared; the peer median is $283.99M.
- Total equity amounts to 92.3% of total assets for KLRA, versus a peer median of 88.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | Jun 2026 | $1.12B | — | — | 92.3% |
| Jun 2026 | $631.42M | -18.9% | +16.7% | 89.6% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $472.95M | +22.0% | — | 94.5% |
| Jun 2026 | $408.32M | -48.7% | +63.8% | 78.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $379.12M | +21.1% | — | 95.3% |
| Mar 2026 | $283.99M | +99.8% | +6.7% | 84.6% | |
| Mar 2026 | $238.28M | +70.3% | +9.7% | 88.6% | |
| Mar 2026 | $89.96M | +911.1% | +122.6% | 91.0% | |
| Mar 2026 | $21.38M | +235.3% | — | 21.5% | |
| Mar 2026 | $18.72M | -34.9% | -35.2% | 40.4% | |
| Peer median (excluding KLRA) | $283.99M | +22.0% | +13.2% | 88.6% | |
Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2025 Dec 2025 |
|---|---|
| Cash & Equivalents | 160.27M |
| Short-term Investments | 385.79M |
| Net Receivables | 2.73M |
| Inventory | 0 |
| Other Current Assets | 1.23M |
| Total Current Assets | 557.54M |
| Property, Plant & Equipment (Net) | 12.42M |
| Goodwill | 0 |
| Intangible Assets | 0 |
| Long-term Investments | 106.67M |
| Tax Assets | 0 |
| Other Non-current Assets | 15.67M |
| Total Non-current Assets | 134.76M |
| Total Assets | 692.29M |
| Account Payables | 7.53M |
| Short-term Debt | 0 |
| Tax Payables | 0 |
| Deferred Revenue | 0 |
| Other Current Liabilities | 9.97M |
| Total Current Liabilities | 46.41M |
| Long-term Debt | 0 |
| Deferred Tax Liabilities | 0 |
| Deferred Revenue (Non-current) | 0 |
| Other Non-current Liabilities | 992.63M |
| Total Non-current Liabilities | 1B |
| Total Liabilities | 1.05B |
| Common Stock | 0 |
| Retained Earnings | (368.67M) |
| Accumulated OCI | 229K |
| Other Stockholders Equity | 0 |
| Minority Interest | 0 |
| Total Equity | (356.46M) |
| Total Debt | 10.75M |
| Net Debt | (149.51M) |
Kailera Therapeutics, Inc.
NASDAQ:KLRA
Intrinsic Alpha fair value
Locked
Current Price
$11.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.